rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
Clonal Hematopoiesis in Ovarian Cancer Survivors and Risk of Secondary Blood Cancers
Status: Recruiting

This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  * Subjects will have or had ovarian cancer and are on or have completed PARPi maintenance therapy  Or have been diagnosed with ovarian cancer as well as clonal hematopoiesis of indeterminate potential Have a life expectancy of greater than 6 months  Exclusion Criteria:  * Individuals with a life expectancy of less than 6 months - HealthyVolunteers: No - Gender: Female - StdAgeList: Child, Adult, Older Adult - StudyPopulation: Subjects will have or had ovarian cancer and are on or have completed PARPi maintenance therapy or have been diagnosed with ovarian cancer as well as clonal hematopoiesis of indeterminate potential - SamplingMethod: Non-Probability Sample
Hydroxytyrosol Dietary Supplement and Prevention of Age-Related Diseases
Status: Recruiting

The primary objective of this study is to ascertain the effects of chronic consumption of a hydroxytyrosol-rich extract from olive (Hytolive®) in a population at high risk of developing age-related pathologies such as type 2 diabetes and cardiovascular diseases. The markers measured will be associated with oxidative stress, inflammation, and homeostasis glucose and lipid profiles. Improvements in these parameters could potentially prevent the onset of pathologies associated with aging.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Prediabetes (defined as fasting glucose levels according to the American Diabetes Association guideline, with fasting blood glucose ≥100 and <126 mg/dL, or hemoglobin A1c levels ranging from 5.7% to 6.4%) Overweight (body mass index BMI 24-29.9 kg/m2)  Exclusion Criteria:  Any prior diagnosis of diabetes, hypertension, hyperlipidemia, other cardiovascular diseases, thyroid gland disorders, asthma, arthritis, or inflammatory conditions, cirrhosis, or other liver diseases Weight loss > 2.5 kg in the last 6 months Being on pharmacological treatment of any kind Taking dietary supplements containing antioxidants other than vitamins Being a smoker or habitual alcohol consumer; being HIV positive Being pregnant or breastfeeding Blood pressure ≥ 140 mmHg (systolic) and ≥ 90 mmHg (diastolic) Total cholesterol ≥ 240 mg/dL, LDL cholesterol ≥ 160 mg/dL, or TG ≥ 200 mg/dl - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 40 Years - MaximumAge: 75 Years - StdAgeList: Adult, Older Adult
The Effect of Aromatherapy Massage on Sleep Quality
Status: Recruiting

Sleep disturbance is one of the most common complaints of patients admitted to ICU. Insufficient sleep in intensive care units may be associated with environmental reasons such as excessive light at night, loud warning sounds and mechanical ventilation alarms, as well as non-environmental factors, including the situation at the time of admission. Sleep assessment is subjective in nature, so it is difficult to perform in the ICU. Since communication with the patient is prevented, clear information about perceived rest and disturbing factors cannot be provided. For this reason, night rest is an issue that is often forgotten and ignored. This study applied a mixture of lavender, medicinal chamomile and neroli oil (in 20 ml of sweet almond oil; lavender oil 2 drops, medicinal chamomile 4 drops, neroli oil 6 drops) to patients who were monitored in intensive care on high-flow and oxygen, once a day for three days. This study will be conducted to determine the effect of aromatherapy massage applied for a total of 30 minutes on sleep quality.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  18 years of age and over, Conscious patients, Staying in intensive care for 24 hours or more, Those with stable hemodynamic status, Receiving O2 therapy, Intubated patients, patients who have passed 24 hours after being extubated, Those whose saturation level is 85 and above  Exclusion Criteria:  Patients with peripheral neuropathy or quadriplegia, Patients with open wounds on their body, Patients receiving analgesia and sedation infusion, Patients who are sedated, Patients in delirium, Patients with allergies detected before starting the application - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Educational Efficacy of VR vs. Simulator in Emergency Medical Training
Status: Not yet recruiting

It has not been revealed which is more effective: an education program using virtual reality technology or a simulation education program using Sim-man.

In this study, the participants are new doctors who graduated from medical school and started working as interns at hospitals. The participants were divided into two groups. One group received a training program using virtual reality technology, and the other group received simulation training using Sim-man. The investigators would like to compare the increase in confidence and satisfaction before and after training.

After the classes and surveys are completed for each group, the participants will be able to receive other educational methods if they wish.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  the medical interns who participate in the education program for medical interns, who will work as interns at Seoul National University Hospital from March 2024 participants who agree to the purpose of the study and consent to participation  Exclusion Criteria:  who do not consent to participate in the study - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - StdAgeList: Child, Adult, Older Adult
The Effect of Aromatherapy Massage on Pain, Anxiety and Comfort
Status: Recruiting

Patients in the intensive care unit (ICU) experience physical and psychological discomfort, including pain. Anxiety is a condition frequently encountered in the ICU. The hospital environment, especially the ICU, is reported as a significant cause of anxiety for patients. Comfort is a holistic, subjective and multidimensional concept that is affected by physical, environmental, social and psycho-spiritual contexts and changes over time and space. Comfort in intensive care is often associated with pain relief and end-of-life care. Assessment tools have been developed to measure patient comfort in the ICU, including levels of pain, delirium, and sedation. This work; Patients who are monitored in intensive care under high-flow and oxygen are treated with a mixture of lavender, thyme and eucalyptus oil (20 ml; lavender oil 5 drops, thyme oil 4 drops, eucalyptus oil 3 drops and 20 ml almond oil) twice a day for three days. This study was conducted to determine the effect of aromatherapy massage applied for a total of 30 minutes on some physiological parameters, pain, anxiety and intensive care comfort of the patients.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  18 years of age and over, Conscious patients, Staying in intensive care for 24 hours or more, Those with stable hemodynamic status, Receiving O2 therapy, Intubated patients, patients who have passed 24 hours after being extubated, Those whose saturation level is 85 and above  Exclusion Criteria:  Patients with peripheral neuropathy or quadriplegia, Patients with open wounds on their body, Patients receiving analgesia and sedation infusion, Patients who are sedated, Patients in delirium, Patients with an allergy detected before starting the application, Patients with a GKS (Glasgow Coma Scale) score of 3 and below - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
The Effects of Cardiac Rehabilitation Programme in Hypertensive Rheumatoid Arthritis Patients
Status: Recruiting

The aim of this study is to investigate the beneficial impacts of the 6-week standardized CR program applied to hypertensive RA patients whose disease activity is under control with regular pharmacological treatment.

Subjects will be randomly assigned to one of two groups: 1.) standard of care (SOC) treatment or 2.) SOC plus a 6 week CR program.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients diagnosed with RA according to ACR/EULAR 2010 criteria Taking regular treatment for at least 1 month according to ACR/EULAR guidelines Patients diagnosed with HT according to the 2018 European Society of Hypertension and European Society of Cardiology (ESH/ESC) guideline  Exclusion Criteria:  Refusing to participate in the program Severe mental disorder Neurological disease or deformity in the lower extremity that would prevent the patient from using the treadmill. High-risk unstable angina and all acute cardiac diseases (acute myocardial infarction, acute endocarditis, myocarditis or pericarditis) Uncontrolled HT, Diabetes, cardiac arrhythmia and heart failure Symptomatic severe aortic stenosis Acute pulmonary embolism or pulmonary infarction and severe pulmonary hypertension - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - StdAgeList: Child, Adult, Older Adult
Method Comparison Study for Measuring Potassium (K) and Ionized Calcium (iCa) in Blood
Status: Not yet recruiting

Method comparison study for Potassium (K) and ionized calcium (iCa).

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Signed and dated consent form (if required by the IRB) ≥ 18 years of age  Exclusion Criteria:  • Prior enrollment in the study - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
The Effectiveness of Chinese Medicine Nuan-gong-ye on Primary Dysmenorrhea
Status: Not yet recruiting

Primary dysmenorrhea is a common under-diagnosed complaint, with a prevalence of about 45-95% in women of childbearing age and about 10-25% in severe cases. Menstrual pain can be classified as primary or secondary. Primary menstrual pain is a crampy pain in the lower abdomen without any pelvic pathology, which usually occurs 6 to 12 months after the first menstruation. Primary menstrual pain is usually most severe on the first day of the menstrual cycle and lasts for 8 to 72 hours. The cause is still unknown, but studies suggest that it may be related to increased prostaglandins, which cause painful contractions of the uterus. The pain is often accompanied by other menstrual discomfort symptoms, including headache, breast tenderness, drowsiness, nausea, vomiting, constipation or diarrhea, and psychological anxiety, depression or irritability. In the case of secondary menstrual pain, there are clear pelvic pathologies, such as endometriosis, uterine fibroids, and pelvic inflammatory disease.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  20-40 year-old women Regular menstrual cycle of 21-35 days, with menstruation lasting 3-7 days Dysmenorrhea started before the age of 20, and have menstrual pain every month No organic lesions on ultrasound within one year (either abdomen or vagina) VAS score above 4 Agree to participate in the study and sign the consent form  Exclusion Criteria:  Has used the same formula of Nuan-gong-ye before. Allergic to Nuan-gong-ye. Has abdominal wounds, infections, or skin diseases. Pregnant or planning to become pregnant within the next five months. Has taken traditional Chinese medicine or prescribed medication for menstrual pain by a Chinese medicine doctor in the past month. Has major illnesses defined by the Taiwan National Health Insurance Administration, such as cancer, heart disease, etc. Has mental illness or cognitive impairment and cannot independently fill out the questionnaire. Has a history of epilepsy or pelvic disorders. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Female - MinimumAge: 20 Years - MaximumAge: 40 Years - StdAgeList: Adult
A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)
Status: Not yet recruiting

The goal of this study is to evaluate the effect of moderate and severe renal impairment (RI) on the pharmacokinetics (PK), safety, and tolerability of MK-8527. There will be no hypothesis testing in the study.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  The main inclusion criteria include but are not limited to the following:  Moderate and Severe RI  With the exception of RI, is in sufficient health for study participation. Has stable renal function.  Healthy  Matches mean age to participants with moderate and severe RI. Has normal renal function.  Exclusion Criteria:  The main exclusion criteria include but are not limited to the following:  All participants  History of cancer (malignancy). Positive test results for Human-immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), or Hepatitis C virus (HCV). Had a major surgery or lost significant volume of blood within 56 days prior to dosing. Donated plasma within 7 days prior to dosing.  Moderate and Severe RI  Failed renal transplant or had a nephrectomy. End stage renal disease requiring dialysis. Any significant arrhythmia or conduction abnormality. Has non-sustained or sustained ventricular tachycardia. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - MaximumAge: 75 Years - StdAgeList: Adult, Older Adult
Prospective Evaluation of the Relation Between Different Questionnaires Measuring Radiation-induced Side-effect
Status: Not yet recruiting

To learn more about how you would rate the intensity or severity of your symptoms during or after radiation therapy using questionnaires with different rating scales.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age ≥18 years English as a primary language Participants with a diagnosis of HNC undergoing active curative RT or having received curative RT within the past 5 years at MD Anderson Ability to complete the survey(s) of their own volition  Exclusion Criteria:  Age < 18 years Non-English speaking participants Participants who are receiving or have received RT in a non-HN site. Participants in follow up and over 5 years from post-treatment Neurocognitive deficits that render patients unable to complete the survey(s) on their own. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Head and Neck Cancer (HNC) participants undergoing active radiation therapy. - SamplingMethod: Non-Probability Sample
Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
Status: Not yet recruiting

The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN).

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  ≥18 years of age Biopsy proven fibrillary glomerulonephritis Proteinuria > 1.0 g/24hrs prior to initiation of immunosuppressive therapy eGFR ≥ 20 ml/min/BSA  Exclusion Criteria:  Secondary FGN (due to monoclonal gammopathy, autoimmune disease or malignancy) Presence of a secondary pathology on biopsy (e.g. diabetic nephropathy) Hepatitis B, C or HIV positive Pregnant or breast-feeding Active infection Kidney transplant Anemia with Hgb < 8.0 g/dL Thrombocytopenia with platelet count < 100'000 Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complication Patients who have received cyclophosphamide in the last 6 months Patients who have received ACTH and/or mycophenolate mofetil in the last 30 days Patient who are on prednisone therapy at a dose > 10 mg/day in the last 15 days Patients who received rituximab previously with CD20 count of < 5 cells/microliter at the time of enrollment For women who are not postmenopausal (greater than or equal to [>/=] 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use two adequate methods of contraception, including at least one method with a failure rate of less than (<) 1 percent (%) per year, during the treatment period and for at least 18 months after the last dose of study drug For men: agreement to remain abstinent or use two adequate methods for contraception, including at least one method with failure rate of less than 1% per year during the treatment period and for at least 6 months (180 days) after the last dose of drug - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Effects of Relighting on Smoke Toxicant Deliveries and Subjective Smoking Measures
Status: Not yet recruiting

Characterize effects of relighting on smoke toxicant deliveries and subjective smoking measures. This will be a within-subject comparison in a single experimental group of 30 smokers who report engaging in relighting behaviors. We will assess smoking intensity for relit and non-relit (i.e., smoked continuously without relighting) cigarettes in the natural environment and will conduct in-clinic measurements of smoking topography and subjective responses for relit and non-relit cigarettes. Information on relighting patterns and smoking topography collected from each participant will be used to compare machine-measured smoke yields of key harmful constituents when their usual cigarettes are smoked with and without relighting. Hypothesis: Relit cigarettes will produce higher levels of toxicants than non-relit cigarettes.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Smoking at least 10 cigarettes/day for at least 1 year (confirmed by CO > 8 ppm or NicAlert test of 6) Engaging in relighting for at least half of their CPD No smoking quit attempts in the past month nor intentions to quit in the next month Stable medical or psychiatric conditions with systolic blood pressure < 160, diastolic blood pressure < 100 and heart rate < 105 bpm  Exclusion Criteria:  Participant with current or recent alcohol or drug abuse problems, use of substances of abuse (other than marijuana due to high prevalence of co-use) within the past month Currently trying or planning to quit smoking in the next month Planning to become pregnant, pregnant or breastfeeding. Pregnancy exclusion will be confirmed through a urine test. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 21 Years - StdAgeList: Adult, Older Adult
Outcomes and Cosmesis With Whole Breast Irradiation and Boost
Status: Not yet recruiting

This study is being done to evaluate cosmetic, patient-reported outcome measures (PROMs), and toxicities for women undergoing ultra-short whole breast irradiation (WBI) therapy with simultaneous integrated boost (SIB). 50 participants will be on study for up to 60 months.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Ability to understand and the willingness to sign a written informed consent document Histologically confirmed early stage (stage T1-T2) invasive carcinoma of the breast or DCIS Breast conserving surgery with negative margins and negative nodes (surgical axillary staging not mandatory), stage N0 or Nx Treatment plan should include breast conserving surgery and adjuvant whole breast irradiation (WBI) therapy delivered with 3D-CRT or IMRT techniques Treatment plan includes breast tumor bed boost Willingness to comply with all study procedures and be available for the duration of the study  Exclusion Criteria:  Mastectomy of ipsilateral breast Lack of histologic diagnosis Histologic involvement of the axillary or regional nodes or metastatic disease Accelerated partial breast irradiation treatment plan Previous history of non-breast malignancy diagnosed in the past 5 years except for basal or squamous cell cancer of the skin Previous history of chest radiation therapy Previous history of ipsilateral breast cancer Concurrent cytotoxic chemotherapy Active connective tissue disease including scleroderma Inability or unwillingness to return for required follow up visit - HealthyVolunteers: No - Gender: Female - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
Status: Not yet recruiting

This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody INBRX-106 combined with the anti-PD-1 antibody pembrolizumab versus pembrolizumab (+ placebo in phase 3) as first-line treatment for patients with locally advanced recurrent or metastatic head and neck squamous cell carcinoma (R/M HSNSCC) incurable by local therapies, expressing PD-L1 with a combined proportion score (CPS) ≥20.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Has histologically or cytologically confirmed diagnosis of metastatic, recurrent head and neck squamous cell carcinoma (HNSCC) that is considered incurable by local therapies. Has tumor PD-L1 expression of CPS ≥20. Tumor tissue must be provided for PD-L1 biomarker analysis. Has human papilloma virus (HPV) testing results for oropharyngeal cancer by p16 immunohistochemistry (IHC) testing. Has measurable disease per RECIST 1.1 guidelines. Has the primary tumor location of the oral cavity, oropharynx, hypopharynx, or larynx. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. Female patients of childbearing potential must have a negative highly sensitive pregnancy test within 72 hours prior to randomization and must not be breastfeeding. Male and female patients of childbearing potential must be willing to completely abstain from heterosexual sex or agree to use a highly effective method of contraception.  Exclusion Criteria:  Has primary tumor site (any histology) of nasopharynx or salivary glands or occult primary site.  Has received prior systemic therapy (eg, prior chemo-, immune-, or biologic therapy) for locally advanced unresectable or metastatic HNSCC.  Prior systemic therapy completed >6 months prior to signing informed consent is allowed if given as part of multimodal treatment for locoregionally advanced disease with curative intent, and no PD/recurrence occurred within 6 months of its completion. Prior systemic immunotherapy in the locoregionally advanced disease with curative intent, including but not limited to anti-PD-(L)1 agents, is allowed if PD/recurrence occurred ≥12 months after its completion. Has clinically active central nervous system metastases and/or carcinomatous meningitis. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. Rapidly progressing disease or with features that may confer a high risk of tumor-associated hemorrhage or uncontrolled tumor pain. Current or history of immune-related disease that required systemic treatment in past 2 years, except for replacement therapy. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult